Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
Abstract Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering im...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1605 |
| _version_ | 1811210436151869440 |
|---|---|
| author | Mahajan Abhishek Ashtekar Renuka Agarwal Ujjwal Choudhari Amit Patil Vijay Noronha Vanita Menon Nandini Prabash Kumar |
| author_facet | Mahajan Abhishek Ashtekar Renuka Agarwal Ujjwal Choudhari Amit Patil Vijay Noronha Vanita Menon Nandini Prabash Kumar |
| author_sort | Mahajan Abhishek |
| collection | DOAJ |
| description | Abstract Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality. |
| first_indexed | 2024-04-12T04:55:30Z |
| format | Article |
| id | doaj.art-35c3282b33c94bc7b94f4f13c56f2cc3 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-04-12T04:55:30Z |
| publishDate | 2022-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-35c3282b33c94bc7b94f4f13c56f2cc32022-12-22T03:47:08ZengWileyCancer Reports2573-83482022-09-0159n/an/a10.1002/cnr2.1605Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case reportMahajan Abhishek0Ashtekar Renuka1Agarwal Ujjwal2Choudhari Amit3Patil Vijay4Noronha Vanita5Menon Nandini6Prabash Kumar7Department of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaDepartment of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute Mumbai Maharashtra IndiaAbstract Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality.https://doi.org/10.1002/cnr2.1605drug‐induced posterior reversible encephalopathy syndromeradioimaginghead and neck cancerimmunotherapyLenvatinib |
| spellingShingle | Mahajan Abhishek Ashtekar Renuka Agarwal Ujjwal Choudhari Amit Patil Vijay Noronha Vanita Menon Nandini Prabash Kumar Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report Cancer Reports drug‐induced posterior reversible encephalopathy syndromeradioimaging head and neck cancer immunotherapy Lenvatinib |
| title | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
| title_full | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
| title_fullStr | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
| title_full_unstemmed | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
| title_short | Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report |
| title_sort | atypical posterior reversible encephalopathy syndrome associated with lenvatinib therapy in a patient with metastatic thyroid cancer a case report |
| topic | drug‐induced posterior reversible encephalopathy syndromeradioimaging head and neck cancer immunotherapy Lenvatinib |
| url | https://doi.org/10.1002/cnr2.1605 |
| work_keys_str_mv | AT mahajanabhishek atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT ashtekarrenuka atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT agarwalujjwal atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT choudhariamit atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT patilvijay atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT noronhavanita atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT menonnandini atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport AT prabashkumar atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport |